Mathilde Cancel

9PUBLICATIONS
27CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

|Sep 04, 2025
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study.

Jerome Alexandre, Philippe Boudier, Elise Lavit

|Aug 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.

Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon

|Jun 13, 2024
Treatment breaks in an oncology unit.

Fanny Vareille, François Chaumier, Claude Linassier

|May 20, 2024
Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature.

Marine Aubert, Laurent Mathiot, Hélène Vegas

|May 06, 2024
FASTOCH: Feasibility of Electronic Patient-Reported Outcomes in Older Patients With Cancer-A Multicenter Prospective Study.

Mathilde Cancel, Carine Sauger, Julie Biogeau

Pageof 2

Frequent Collaborators

2 joint publications

David Crottès

2 joint publications

Pierre Combe

2 joint publications

Gwenaëlle Gravis

1 joint publications

Mehdi Brahmi